Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 15, 2026, titled ""Company Delivers Robust Performance in H2 FY26: Revenue up 18.24% YoY and EBITDA up 4.50% and Growth Led by Volume Expansion and an Improved Product Mix, along with Wider Customer Base and Geographic Reach""